|
🐜
|
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
38 auth.
A. Drilon,
T. Laetsch,
S. Kummar,
S. DuBois,
U. Lassen,
G. Demetri,
M. Nathenson,
R. Doebele,
A. Farago,
A. Pappo,
B. Turpin,
A. Dowlati,
M. Brose,
L. Mascarenhas,
N. Federman,
...
J. Berlin,
W. El-Deiry,
C. Baik,
J. Deeken,
V. Boni,
R. Nagasubramanian,
Matthew H. Taylor,
E. Rudzinski,
F. Meric-Bernstam,
D. Sohal,
P. Ma,
L. Raez,
J. Hechtman,
R. Benayed,
M. Ladanyi,
Brian B. Tuch,
K. Ebata,
S. Cruickshank,
N. Ku,
M. Cox,
D. Hawkins,
D. Hong,
D. Hyman
|
10 |
2018 |
10
🐜
|
|
🐜
|
Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors.
27 auth.
J. Shern,
Li Chen,
J. Chmielecki,
Jun S. Wei,
R. Patidar,
Mara W Rosenberg,
L. Ambrogio,
D. Auclair,
Jianjun Wang,
Young K. Song,
C. Tolman,
Laura Hurd,
Hongling Liao,
Shile Zhang,
D. Bogen,
...
A. Brohl,
Sivasish Sindiri,
D. Catchpoole,
Thomas C. Badgett,
G. Getz,
J. Mora,
James R. Anderson,
S. Skapek,
F. Barr,
M. Meyerson,
D. Hawkins,
Javed Khan
|
9 |
2014 |
9
🐜
|
|
🐜
|
Ewing Sarcoma: Current Management and Future Approaches Through Collaboration.
27 auth.
N. Gaspar,
D. Hawkins,
U. Dirksen,
I. Lewis,
S. Ferrari,
M. Le Deley,
H. Kovar,
R. Grimer,
J. Whelan,
L. Claude,
O. Delattre,
M. Paulussen,
P. Picci,
K. Sundby Hall,
H. van den Berg,
...
R. Ladenstein,
J. Michon,
L. Hjorth,
I. Judson,
R. Luksch,
M. Bernstein,
P. Marec-Berard,
B. Brennan,
A. Craft,
R. Womer,
H. Juergens,
O. Oberlin
|
9 |
2015 |
9
🐜
|
|
🐢
|
Rhabdomyosarcoma
8 auth.
S. Skapek,
A. Ferrari,
Abha A. Gupta,
P. Lupo,
E. Butler,
J. Shipley,
...
F. Barr,
D. Hawkins
|
8 |
2019 |
8
🐢
|
|
🐜
|
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort
52 auth.
S. Smeland,
S. Bielack,
J. Whelan,
M. Bernstein,
P. Hogendoorn,
M. Krailo,
R. Gorlick,
K. Janeway,
F. Ingleby,
J. Anninga,
I. Antal,
C. Arndt,
K. Brown,
T. Butterfaß-Bahloul,
G. Calaminus,
...
M. Capra,
C. Dhooge,
M. Eriksson,
A. Flanagan,
G. Friedel,
M. Gebhardt,
H. Gelderblom,
R. Goldsby,
H. Grier,
R. Grimer,
D. Hawkins,
S. Hecker-Nolting,
K. Sundby Hall,
Michael S. Isakoff,
G. Jovic,
T. Kühne,
L. Kager,
T. von Kalle,
E. Kabíčková,
S. Lang,
C. Lau,
P. Leavey,
S. Lessnick,
L. Mascarenhas,
R. Mayer‐Steinacker,
P. Meyers,
R. Nagarajan,
R. Randall,
P. Reichardt,
M. Renard,
C. Rechnitzer,
C. Schwartz,
S. Strauss,
L. Teot,
B. Timmermann,
M. Sydes,
N. Marina
|
8 |
2019 |
8
🐜
|
|
🐢
|
Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
18 auth.
T. Laetsch,
S. DuBois,
L. Mascarenhas,
B. Turpin,
N. Federman,
C. Albert,
R. Nagasubramanian,
Jessica L. Davis,
E. Rudzinski,
Angela Feraco,
...
Brian B. Tuch,
K. Ebata,
M. Reynolds,
Steve Smith,
S. Cruickshank,
M. Cox,
A. Pappo,
D. Hawkins
|
8 |
2018 |
8
🐢
|
|
🐜
|
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial
53 auth.
N. Marina,
S. Smeland,
S. Bielack,
M. Bernstein,
G. Jovic,
M. Krailo,
J. Hook,
C. Arndt,
H. van den Berg,
B. Brennan,
B. Brichard,
K. Brown,
T. Butterfaß-Bahloul,
G. Calaminus,
H. Daldrup-Link,
...
M. Eriksson,
M. Gebhardt,
H. Gelderblom,
J. Gerss,
R. Goldsby,
A. Goorin,
R. Gorlick,
H. Grier,
J. Hale,
K. S. Hall,
J. Hardes,
D. Hawkins,
K. Helmke,
P. Hogendoorn,
Michael S. Isakoff,
K. Janeway,
H. Jürgens,
L. Kager,
T. Kühne,
C. Lau,
P. Leavey,
S. Lessnick,
L. Mascarenhas,
P. Meyers,
H. Mottl,
M. Nathrath,
Z. Pápai,
R. Randall,
P. Reichardt,
M. Renard,
A. Safwat,
C. Schwartz,
M. Stevens,
S. Strauss,
L. Teot,
M. Werner,
M. Sydes,
J. Whelan
|
8 |
2016 |
8
🐜
|
|
🐢
|
Rhabdomyosarcoma: Review of the Children's Oncology Group (COG) soft‐tissue Sarcoma committee experience and rationale for current COG studies
S. Malempati,
D. Hawkins
|
8 |
2012 |
8
🐢
|
|
🦁
|
Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents.
D. Hawkins,
Demers Gw,
Galloway Da
|
8 |
1996 |
8
🦁
|
|
🐜
|
Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.
13 auth.
C. Arndt,
J. Stoner,
D. Hawkins,
D. Rodeberg,
A. Hayes-Jordan,
C. Paidas,
D. Parham,
L. Teot,
M. Wharam,
J. Breneman,
...
S. Donaldson,
James R. Anderson,
W. Meyer
|
8 |
2009 |
8
🐜
|
|
🐜
|
Genome-Informed Targeted Therapy for Osteosarcoma.
21 auth.
L. Sayles,
Marcus R. Breese,
Amanda L Koehne,
Stanley G Leung,
Alex G. Lee,
Heng-Yi Liu,
Aviv Spillinger,
A. Shah,
Bogdan Tanasa,
Krystal M. Straessler,
...
F. Hazard,
Sheri L Spunt,
N. Marina,
Grace E. Kim,
Soo-Jin Cho,
R. Avedian,
D. Mohler,
Mi-Ok Kim,
S. G. Dubois,
D. Hawkins,
E. A. Sweet-Cordero
|
8 |
2018 |
8
🐜
|
|
🦁
|
[18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors.
7 auth.
D. Hawkins,
S. Schuetze,
J. Butrynski,
J. Rajendran,
C. Vernon,
E. Conrad,
...
J. Eary
|
7 |
2005 |
7
🦁
|
